Previous close | 79.10 |
Open | 78.36 |
Bid | 77.70 x 0 |
Ask | 77.76 x 0 |
Day's range | 77.76 - 79.56 |
52-week range | 61.26 - 121.65 |
Volume | |
Avg. volume | 568,450 |
Market cap | 20.708B |
Beta (5Y monthly) | 0.63 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 15 Dec 2021 |
1y target est | N/A |
In Q3 2022/23, Ambu delivered 8% organic revenue growth and a 7.6% EBIT margin. This was driven by Endoscopy Solutions growing 23%, due to high double-digit growth within urology and ENT, and pulmonology returning to positive growth year-over-year. Today, Ambu narrows its full-year 2022/23 organic revenue growth guidance to 6-8%, previously 5-8%, based on the company’s performance in Q3 and the first two months of Q4. On 10 July 2023, Ambu adjusted its financial guidance by upgrading its full-ye
Pursuant to Ambu A/S’ (Ambu) Remuneration Policy, a total of 198,872 Performance Share Units (PSUs) related to Ambu’s long-term incentive programme (LTIP) for 2022/23 have been granted on 28 July 2023. 55,956 of the PSUs have been granted to the Executive Management and 142,916 of the PSUs have been granted to other key employees. The LTIP covers the financial year 2022/23, and the final allocation of PSUs will be within the range of 0-200% of the initial grant, subject to the actual achievement
Ambu raises its expectations for EBIT margin before special items to 5 - 6% (previously 3 - 5%) for the full-year 2022/23, based on its preliminary Q3 results. For Q3 2022/23, EBIT before special items totalled DKK 91m (DKK 42m), with an EBIT-margin before special items of 7.6% (3.7%), mainly driven by a better-than-expected gross margin, based on product mix and lower distribution costs. PRELIMINARY FINANCIAL HIGHLIGHTS FOR Q3 2022/23Last year’s comparative figures are stated in brackets. Reven